Alefacept modifies long-term disease severity and improves the response to other treatments

European Journal of Dermatology

Volumn 15, Issue 5, 2005, Pages 366-373

  Van Duijnhoven, M W F ^a   De Jong, E M G J ^a   Gerritsen, W J ^a   Pasch, M C ^a   Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alefacept; Biologicals; Inflammation; Psoriasis

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CYCLOSPORIN; DITHRANOL; ETRETIN; FUMARIC ACID; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LONG TERM CARE; MALE; PATIENT CARE; PSORIASIS; PUVA; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS;

EID: 25144468867     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000; 292: 519-21.
2. Pastore S, Mascia F, Mariotti F, Dattilo C, Girolomoni G. Chemokine networks in inflamatory skin diseases. Eur J Dermatol 2004; 14(4): 203-8.
3. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-22.
4. Chisholm PL, Williams CA, Jones WE, Majeau GR, Oleson FB, Burrus-Fischer B. The effects of an immunomodulatory LFAS-IgG, fusion protein on nonhuman primates. Ther Immunol 1994; 1: 205-16.
5. Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB. Immunomodulation by LFA3TIP, an LFA-3/IgG, fusion protein: cell line dependent glycocylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 1995; 2: 159-71.
6. Ortonne JP, Prinz JC. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Eur J Dermatol 2004; 14(1): 41-5.
7. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3,CD2,and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988; 140: 1401-7.
8. Majeau GR, Whitty A, Yim K, Meier W, Hochman PS. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells independent of cell activation. Cell Adhes Commun 1999; 7: 267-79.
9. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753-67.
10. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55.
11. Ortonne JP, Lebwohl M, Griffiths C. Alefacept Clinical Study Group. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical respons in patients with chronic plaque psoriasis. Eur J Dermatol 2003; 13(2): 117-23.
12. Gottlieb A, Casale T, Goffe B, Gordon K, Korman N, Lowe N. Impast of a 12-week course of alefacept therapy on primary and secondary immune responses in psoriasis patients. J Eur Acad Dermatol Venereol 2001; 15(Suppl 2): 242; [abstract (Abstract P24-21)].
13. Ellis C, Krueger G, Shrager D. Repeated courses of alefacept therapy in chronic plaque psoriasis provide consistent efficacy and safety. J Eur Acad Dermatol Venereol 2001; 15(Suppl 2): 246; [(abstract) Abstract P24-38].
14. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-33.
15. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E. Integrating biological therapies into psoriasis management: International Consensus Conference. Br J Dermatol 2004; 151(suppl 69): 3-17.
16. Lederle Pharmaceutical. Methotrexate sodium tablets, methotrexate sodium for injection, methotrexate LPF® sodium (methotrexate sodium injection) and methotrexate sodium injection. Pearl River, NY: Lederle Pharmaceutical, August 2001; (package insert).
17. Roche Laboratories Inc. Soriatane® (acitretin) capsules. Nutley, NJ: Roche Laboratories Inc, 1998; (package insert).
18. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid ester: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999; 141: 424-9.
19. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with furnatic acid ester: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998; 138: 456-60.
20. Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363-9.
21. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis. Results and side effects of 2 years treatment. J Am Acad Dermatol 1992; 27: 769-71.
22. Calzavara-Pinton PG, Carlino A, Manfredi E, et al. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol 1994; 186(Suppl.): 164-5; (Stockh).
23. ICN Pharmaceuticals Inc. Oxsoralen-Ultra® capsules(methoxsalen capsules, USP, 10 mg). Costa Mesa, CA: ICN Pharmaceuticals Inc, 1998; (package insert).
24. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25: 1-10.
25. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132: 623-9.
26. Zachariae H. Renal toxicity of long-term cyclosporin. Scand J Rheumatol 1999; 28: 65-8.
27. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206: 307-15.
28. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related qualify of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003; 4: 131-9.
29. Swinkels OQ, Prins M, Gerritsen MJ, et al. An immunohistochemical assessment of the response of the psoriatic lesion to single and repeated application of high dose dithranol cream. Skin Pharmacol Appl Skin Physiol 2002; 15: 393-400.